User menu

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.

Bibliographic reference Li, Su-Chen ; Martijn, Cécile ; Cui, Tao ; Essaghir, Ahmed ; Luque, Raúl M ; et. al. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.. In: PLoS One, Vol. 7, no. 10, p. e48411 (2012)
Permanent URL http://hdl.handle.net/2078/120344
  1. KLÖPPEL GÜNTER, PERREN AUREL, HEITZ PHILIPP U., The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification, 10.1196/annals.1294.002
  2. Gustafsson Björn I, Kidd Mark, Modlin Irvin M, Neuroendocrine tumors of the diffuse neuroendocrine system : , 10.1097/cco.0b013e3282f1c595
  3. Bosman TF, Carneiro F, Hruban RH, Theise ND, editors (2010) WHO Classification of Tumours of the Digestive System 4ed. Lyon IARC. 13 p.
  4. Modlin Irvin M, Oberg Kjell, Chung Daniel C, Jensen Robert T, de Herder Wouter W, Thakker Rajesh V, Caplin Martyn, Delle Fave Gianfranco, Kaltsas Greg A, Krenning Eric P, Moss Steven F, Nilsson Ola, Rindi Guido, Salazar Ramon, Ruszniewski Philippe, Sundin Anders, Gastroenteropancreatic neuroendocrine tumours, 10.1016/s1470-2045(07)70410-2
  5. Boudreaux J. Philip, Klimstra David S., Hassan Manal M., Woltering Eugene A., Jensen Robert T., Goldsmith Stanley J., Nutting Charles, Bushnell David L., Caplin Martyn E., Yao James C., The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors : Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum, 10.1097/mpa.0b013e3181ebb2a5
  6. Kulke Matthew H., Siu Lillian L., Tepper Joel E., Fisher George, Jaffe Deborah, Haller Daniel G., Ellis Lee M., Benedetti Jacqueline K., Bergsland Emily K., Hobday Timothy J., Van Cutsem Eric, Pingpank James, Oberg Kjell, Cohen Steven J., Posner Mitchell C., Yao James C., Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting, 10.1200/jco.2010.33.2056
  7. Pavel Marianne E, Hainsworth John D, Baudin Eric, Peeters Marc, Hörsch Dieter, Winkler Robert E, Klimovsky Judith, Lebwohl David, Jehl Valentine, Wolin Edward M, Öberg Kjell, Van Cutsem Eric, Yao James C, Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study, 10.1016/s0140-6736(11)61742-x
  8. Strosberg Jonathan, Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors, 10.3748/wjg.v16.i24.2963
  9. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP (2010) Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139: 742–753, 753 e741.
  10. Culler Michael D., Öberg Kjell, Arnold Rudolf, Krenning Eric P., Sevilla Isabel, Díaz José Ángel, Somatostatin analogs for the treatment of neuroendocrine tumors, 10.1007/s10555-011-9293-0
  11. KE Oberg, Clin Oncol (R Coll Radiol), 6, 49 (2011)
  12. Öberg K. E., Gastrointestinal neuroendocrine tumors, 10.1093/annonc/mdq290
  13. Rinke Anja, Müller Hans-Helge, Schade-Brittinger Carmen, Klose Klaus-Jochen, Barth Peter, Wied Matthias, Mayer Christina, Aminossadati Behnaz, Pape Ulrich-Frank, Bläker Michael, Harder Jan, Arnold Christian, Gress Thomas, Arnold Rudolf, Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group, 10.1200/jco.2009.22.8510
  14. Chua Yu Jo, Michael Michael, Zalcberg John R., Hicks Rod J., Goldstein David, Liauw Winston, Price Timothy, Antitumor Effect of Somatostatin Analogs in Neuroendocrine Tumors, 10.1200/jco.2009.26.0612
  15. Öberg Kjell E., Is It Time to Widen the Use of Somatostatin Analogs in Neuroendocrine Tumors?, 10.1200/jco.2009.23.6711
  16. Martino Maria Cristina De, Hofland Leo J., Lamberts Steven W.J., Somatostatin and Somatostatin Receptors: from Basic Concepts to Clinical Applications, Neuroendocrinology - Pathological Situations and Diseases (2010) ISBN:9780444536167 p.255-280, 10.1016/s0079-6123(10)82011-4
  17. Msaouel Pavlos, Galanis Evanthia, Koutsilieris Michael, Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology, 10.1517/13543780903176399
  18. Sideris L., Dube P., Rinke A., Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors, 10.1634/theoncologist.2011-0458
  19. Leu F. P., Nandi M., Niu C., The Effect of Transforming Growth Factor   on Human Neuroendocrine Tumor BON Cell Proliferation and Differentiation Is Mediated through Somatostatin Signaling, 10.1158/1541-7786.mcr-07-2073
  20. Walter Thomas, Hommell-Fontaine Juliette, Gouysse Géraldine, Pourreyron Céline, Nejjari Mimoun, Villaume Karine, Causeret Sylvain, Hervieu Valérie, Poncet Gilles, Roche Colette, Scoazec Jean-Yves, Effects of Somatostatin and Octreotide on the Interactions between Neoplastic Gastroenteropancreatic Endocrine Cells and Endothelial Cells: A Comparison between in vitro and in vivo Properties, 10.1159/000328134
  21. Vikman Sofia, Essand Magnus, Cunningham Janet L., Torre Manuel de la, Öberg Kjell, Tötterman Thomas H., Giandomenico Valeria, Gene expression in midgut carcinoid tumors: Potential targets for immunotherapy, 10.1080/02841860510007404
  22. Leja J., Dzojic H., Gustafson E., Oberg K., Giandomenico V., Essand M., A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy, 10.1158/1078-0432.ccr-06-2532
  23. VM Alexander, Int J Clin Exp Med, 3, 95 (2010)
  24. Leja J, Nilsson B, Yu D, Gustafson E, Akerstrom G, et al.. (2010) Double-Detargeted Oncolytic Adenovirus Shows Replication Arrest in Liver Cells and Retains Neuroendocrine Cell Killing Ability. PLoS ONE 5.
  25. Wu S. Vincent, Yuan Pu-Qing, Lai Jim, Wong Kelvin, Chen Monica C., Ohning Gordon V., Taché Yvette, Activation of Type 1 CRH Receptor Isoforms Induces Serotonin Release from Human Carcinoid BON-1N Cells: An Enterochromaffin Cell Model, 10.1210/en.2010-0997
  26. Leja J, Yu D, Nilsson B, Gedda L, Zieba A, Hakkarainen T, Åkerström G, Öberg K, Giandomenico V, Essand M, Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells, 10.1038/gt.2011.54
  27. Van Buren G., Rashid A., Yang A. D., Abdalla E. K., Gray M. J., Liu W., Somcio R., Fan F., Camp E. R., Yao J. C., Ellis L. M., The Development and Characterization of a Human Midgut Carcinoid Cell Line, 10.1158/1078-0432.ccr-06-2723
  28. Modlin Irvin M., Kidd Mark, Pfragner Roswitha, Eick Geeta N., Champaneria Manish C., The Functional Characterization of Normal and Neoplastic Human Enterochromaffin Cells, 10.1210/jc.2006-0110
  29. M Kaku, Gann, 71, 596 (1980)
  30. Rodrigo Juan P., García-Pedrero Juana M., Llorente José L., Fresno Manuel F., Allonca Eva, Suarez Carlos, Hermsen Mario, Down-regulation of annexin A1 and A2 protein expression in intestinal-type sinonasal adenocarcinomas☆, 10.1016/j.humpath.2010.05.017
  31. Zinovyeva M. V., Monastyrskaya G. S., Kopantzev E. P., Vinogradova T. V., Kostina M. B., Sass A. V., Filyukova O. B., Uspenskaya N. Y., Sukhikh G. T., Sverdlov E. D., Identification of some human genes oppositely regulated during esophageal squamous cell carcinoma formation and human embryonic esophagus development, 10.1111/j.1442-2050.2009.01008.x
  32. Dhasarathy Archana, Phadke Dhiral, Mav Deepak, Shah Ruchir R., Wade Paul A., The Transcription Factors Snail and Slug Activate the Transforming Growth Factor-Beta Signaling Pathway in Breast Cancer, 10.1371/journal.pone.0026514
  33. Sethi Gautam, Sung Bokyung, Aggarwal Bharat B., Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer, Advances in Experimental Medicine and Biology (2009) ISBN:9780387895192 p.207-215, 10.1007/978-0-387-89520-8_15
  34. Joshi Jayashree P., Brown Nicole E., Griner Samantha E., Nahta Rita, Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells, 10.1016/j.bcp.2011.07.082
  35. Kim T. Y., Vigil D., Der C. J., Juliano R. L., Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility, 10.1007/s10555-008-9167-2
  36. Maeda M., Hasegawa H., Hyodo T., Ito S., Asano E., Yuang H., Funasaka K., Shimokata K., Hasegawa Y., Hamaguchi M., Senga T., ARHGAP18, a GTPase-activating protein for RhoA, controls cell shape, spreading, and motility, 10.1091/mbc.e11-04-0364
  37. Zhang J., Cao W., Xu Q., Chen W.-t., The expression of EMP1 is downregulated in oral squamous cell carcinoma and possibly associated with tumour metastasis, 10.1136/jcp.2010.082404
  38. de Graauw M., van Miltenburg M. H., Schmidt M. K., Pont C., Lalai R., Kartopawiro J., Pardali E., Le Devedec S. E., Smit V. T., van der Wal A., Van't Veer L. J., Cleton-Jansen A.-M., ten Dijke P., van de Water B., Annexin A1 regulates TGF-  signaling and promotes metastasis formation of basal-like breast cancer cells, 10.1073/pnas.0913360107
  39. Petrella Antonello, Festa Michela, Ercolino S.F., Zerilli M., Stassi Giorgio, Solito Egle, Parente Luca, Annexin-1 downregulation in thyroid cancer correlates to the degree of tumour differentiation, 10.4161/cbt.5.6.2700
  40. Ching Yick-Pang, Wong Chun-Ming, Chan Shing-Fai, Leung Thomas Ho-Yin, Ng David Chi-Heng, Jin Dong-Yan, Ng Irene Oi-lin, Deleted in Liver Cancer (DLC) 2 Encodes a RhoGAP Protein with Growth Suppressor Function and Is Underexpressed in Hepatocellular Carcinoma, 10.1074/jbc.m208310200
  41. Hur Gyu Young, Lee Sung Yong, Lee Seung Hyeun, Kim Se Joong, Lee Kyoung Ju, Jung Jin Yong, Lee Eun Joo, Kang Eun Hae, Jung Ki Hwan, Lee Sang Yeub, Kim Je Hyeong, Shin Chol, Shim Jae Jeong, In Kwang Ho, Kang Kyung Ho, Yoo Se Hwa, Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation, 10.1038/emm.2007.41
  42. Jain A., Tindell C. A., Laux I., Hunter J. B., Curran J., Galkin A., Afar D. E., Aronson N., Shak S., Natale R. B., Agus D. B., Epithelial membrane protein-1 is a biomarker of gefitinib resistance, 10.1073/pnas.0502113102
  43. You B, Chen EX (2011) Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab. J Clin Pharmacol.
  44. Staff Anne Cathrine, Bock Annika J., Becker Caroline, Kempf Tibor, Wollert Kai C., Davidson Ben, Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer, 10.1016/j.ygyno.2010.05.032
  45. Costa V. L., Henrique R., Danielsen S. A., Duarte-Pereira S., Eknaes M., Skotheim R. I., Rodrigues A., Magalhaes J. S., Oliveira J., Lothe R. A., Teixeira M. R., Jeronimo C., Lind G. E., Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples, 10.1158/1078-0432.ccr-10-1312
  46. Bellam Naresh, Pasche Boris, TGF-β Signaling Alterations and Colon Cancer, Cancer Treatment and Research (2010) ISBN:9781441960320 p.85-103, 10.1007/978-1-4419-6033-7_5
  47. Wimmel A, Autocrine growth inhibition by transforming growth factor  -1 (TGF -1) in human neuroendocrine tumour cells, 10.1136/gut.52.9.1308
  48. Trobridge Patty, Knoblaugh Sue, Washington M. Kay, Munoz Nina M., Tsuchiya Karen D., Rojas Andres, Song Xiaoling, Ulrich Cornelia M., Sasazuki Takehiko, Shirasawa Senji, Grady William M., TGF-β Receptor Inactivation and Mutant Kras Induce Intestinal Neoplasms in Mice via a β-Catenin-Independent Pathway, 10.1053/j.gastro.2009.01.066
  49. Schreiber Taylor H., Wolf Dietlinde, Podack Eckhard R., The Role of TNFRSF25:TNFSF15 in Disease… and Health?, Advances in Experimental Medicine and Biology (2011) ISBN:9781441966117 p.289-298, 10.1007/978-1-4419-6612-4_30
  50. Martinez-Alonso M, Llecha N, Mayorga ME, Sorolla A, Dolcet X, Sanmartin V, Abal L, Casanova JM, Baradad M, Yeramian A, Egido R, Puig S, Vilella R, Matias-Guiu X, Marti RM, Expression of Somatostatin Receptors in Human Melanoma Cell Lines: Effect of Two Different Somatostatin Analogues, Octreotide and SOM230, on Cell Proliferation, 10.1177/147323000903700617
  51. Arnold R., Simon B., Wied M., Treatment of Neuroendocrine GEP Tumours with Somatostatin Analogues, 10.1159/000051861
  52. Hofland Leo J., Lamberts Steven W. J., The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance, 10.1210/er.2000-0001
  53. Kidd Mark, Schally Andrew V., Pfragner Roswitha, Malfertheiner Maximillian V., Modlin Irvin M., Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors, 10.1002/cncr.23303
  54. Saeed AI, Hagabati NK, Braisted JC, Liang W, Sharov V, et al.. (2006) TM4 microarray software suite. Methods Enzymol 411: 134-+.
  55. Durán-Prado Mario, Gahete Manuel D., Martínez-Fuentes Antonio J., Luque Raúl M., Quintero Ana, Webb Susan M., Benito-López Pedro, Leal Alfonso, Schulz Stefan, Gracia-Navarro F., Malagón María M., Castaño Justo P., Identification and Characterization of Two Novel Truncated but Functional Isoforms of the Somatostatin Receptor Subtype 5 Differentially Present in Pituitary Tumors, 10.1210/jc.2008-2564
  56. Livak Kenneth J., Schmittgen Thomas D., Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method, 10.1006/meth.2001.1262
  57. Cui T, Hurtig M, Elgue G, Li SC, Veronesi G, et al.. (2010) Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors. PLoS ONE 5.